Castle Biosciences, Inc. (CSTL) Surpasses Q4 Earnings and Revenue Estimates

Company Performance - Castle Biosciences reported quarterly earnings of $0.32 per share, exceeding the Zacks Consensus Estimate of $0.11 per share, compared to a loss of $0.10 per share a year ago, representing an earnings surprise of 190.91% [1] - The company posted revenues of $86.31 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.65%, and showing an increase from year-ago revenues of $66.12 million [2] - Over the last four quarters, Castle Biosciences has consistently surpassed consensus EPS estimates [2] Stock Performance - Castle Biosciences shares have declined approximately 2.3% since the beginning of the year, while the S&P 500 has gained 1.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.07 on revenues of $84.85 million, and for the current fiscal year, it is -$1.51 on revenues of $314.15 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Castle Biosciences belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]